(Q45367792)

13 December 2017

title

Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients (English)

1 reference

13 December 2017

1 reference

S I Martin

1

1 reference

13 December 2017

B Dodson

2

1 reference

13 December 2017

C Wheeler

3

1 reference

13 December 2017

J Davis

4

1 reference

13 December 2017

T Pesavento

5

1 reference

13 December 2017

G L Bumgardner

6

1 reference

13 December 2017

language of work or name

English

0 references

publication date

30 March 2011

1 reference

American Journal of Transplantation

13 December 2017

published in

1 reference

13 December 2017

volume

11

1 reference

13 December 2017

issue

5

1 reference

13 December 2017

page(s)

1058-1063

1 reference

Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Case report: Kinetics of Epstein-Barr virus load in a bone marrow transplant patient with no sign of lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03478.X

10.1111/J.1600-6143.2011.03478.X

21 January 2018

Identifiers

DOI

1 reference

13 December 2017

1 reference